Literature DB >> 22396430

Effects of confounders and intermediates on the association of bacteraemia caused by extended-spectrum β-lactamase-producing Enterobacteriaceae and patient outcome: a meta-analysis.

Wouter C Rottier1, Heidi S M Ammerlaan, Marc J M Bonten.   

Abstract

BACKGROUND AND OBJECTIVES: Bacteraemia caused by Enterobacteriaceae (EB) producing extended-spectrum β-lactamase (ESBL+) has been associated with higher mortality compared with non-ESBL-producing (ESBL-) EB bacteraemia in observational studies. We conducted a systematic review and meta-analysis of these studies to assess how adjusting for confounding in multivariate analyses affects the pooled estimate, and whether multivariate analyses that include intermediates in the causal pathway of outcome (sepsis severity and inadequate empirical therapy) have lower estimates of attributable mortality. DATA SOURCES: PubMed search on 23 November 2010 followed by manually searching reference lists of included studies. STUDY ELIGIBILITY CRITERIA: Cohort studies published in English with separate mortality rates for ESBL+ and ESBL- EB bacteraemia. SYNTHESIS
METHODS: Random-effects pooling of unadjusted and adjusted ORs followed by subgroup analyses to explore effects of adjustment procedures on adjusted ORs.
RESULTS: The pooled OR for the unadjusted mortality associated with ESBL production was 2.35 (95% CI 1.90-2.91, I(2) = 42%, 32 studies). The pooled adjusted OR was 1.52 (95% CI 1.15-2.01, I(2) = 32%, 15 studies). Adjustment for more intermediates was associated with decreasing ORs. The pooled OR for the analyses adjusting for inadequate empirical therapy was 1.37 (95% CI 1.04-1.82).
CONCLUSIONS: ESBL production in EB bacteraemia is associated with a higher mortality compared with bacteraemia with ESBL- EB, although the estimate of this association is affected by adjustment procedures. Adjustment for inadequate empirical therapy leads to a reduction in ORs, indicating that higher mortality is likely to be mediated through this phenomenon.

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 22396430     DOI: 10.1093/jac/dks065

Source DB:  PubMed          Journal:  J Antimicrob Chemother        ISSN: 0305-7453            Impact factor:   5.790


  68 in total

Review 1.  Intestinal Carriage of Carbapenemase-Producing Organisms: Current Status of Surveillance Methods.

Authors:  Roberto Viau; Karen M Frank; Michael R Jacobs; Brigid Wilson; Keith Kaye; Curtis J Donskey; Federico Perez; Andrea Endimiani; Robert A Bonomo
Journal:  Clin Microbiol Rev       Date:  2016-01       Impact factor: 26.132

2.  Use of an Enrichment Broth Improves Detection of Extended-Spectrum-Beta-Lactamase-Producing Enterobacteriaceae in Clinical Stool Samples.

Authors:  Nathalie Jazmati; Rebecca Hein; Axel Hamprecht
Journal:  J Clin Microbiol       Date:  2015-11-25       Impact factor: 5.948

3.  Risk factors for extended-spectrum beta-lactamase-producing Enterobacteriales infection: are they the same in neutropenic and non-neutropenic patients?

Authors:  Filippo Lagi; Giampaolo Corti
Journal:  Intern Emerg Med       Date:  2019-02-08       Impact factor: 3.397

4.  Rectal Carriage of Extended-Spectrum-Beta-Lactamase-Producing Enterobacteriaceae in Hospitalized Patients: Selective Preenrichment Increases Yield of Screening.

Authors:  M F Q Kluytmans-van den Bergh; C Verhulst; L E Willemsen; E Verkade; M J M Bonten; J A J W Kluytmans
Journal:  J Clin Microbiol       Date:  2015-05-20       Impact factor: 5.948

5.  Appropriate non-carbapenems are not inferior to carbapenems as initial empirical therapy for bacteremia caused by extended-spectrum beta-lactamase-producing Enterobacteriaceae: a propensity score weighted multicenter cohort study.

Authors:  J-H Ko; N R Lee; E-J Joo; S-Y Moon; J-K Choi; D A Park; K R Peck
Journal:  Eur J Clin Microbiol Infect Dis       Date:  2017-11-25       Impact factor: 3.267

6.  Development and validation of the INCREMENT-ESBL predictive score for mortality in patients with bloodstream infections due to extended-spectrum-β-lactamase-producing Enterobacteriaceae.

Authors:  Zaira Raquel Palacios-Baena; Belén Gutiérrez-Gutiérrez; Marina De Cueto; Pierluigi Viale; Mario Venditti; Alicia Hernández-Torres; Antonio Oliver; Luis Martínez-Martínez; Esther Calbo; Vicente Pintado; Oriol Gasch; Benito Almirante; José Antonio Lepe; Johann Pitout; Murat Akova; Carmen Peña-Miralles; Mitchell J Schwaber; Mario Tumbarello; Evelina Tacconelli; Julia Origüen; Nuria Prim; German Bou; Helen Giamarellou; Joaquín Bermejo; Axel Hamprecht; Federico Pérez; Manuel Almela; Warren Lowman; Po-Ren Hsueh; Carolina Navarro-San Francisco; Julián Torre-Cisneros; Yehuda Carmeli; Robert A Bonomo; David L Paterson; Álvaro Pascual; Jesús Rodríguez-Baño
Journal:  J Antimicrob Chemother       Date:  2017-03-01       Impact factor: 5.790

Review 7.  Clinical management of infections caused by multidrug-resistant Enterobacteriaceae.

Authors:  Mercedes Delgado-Valverde; Jesús Sojo-Dorado; Alvaro Pascual; Jesús Rodríguez-Baño
Journal:  Ther Adv Infect Dis       Date:  2013-04

8.  Impact of extended-spectrum β-lactamase production on treatment outcomes of acute pyelonephritis caused by escherichia coli in patients without health care-associated risk factors.

Authors:  Sun Hee Park; Su-Mi Choi; Dong-Gun Lee; Sung-Yeon Cho; Hyo-Jin Lee; Jae-Ki Choi; Jung-Hyun Choi; Jin-Hong Yoo
Journal:  Antimicrob Agents Chemother       Date:  2015-01-12       Impact factor: 5.191

9.  Whole-Genome Multilocus Sequence Typing of Extended-Spectrum-Beta-Lactamase-Producing Enterobacteriaceae.

Authors:  Marjolein F Q Kluytmans-van den Bergh; John W A Rossen; Patricia C J Bruijning-Verhagen; Marc J M Bonten; Alexander W Friedrich; Christina M J E Vandenbroucke-Grauls; Rob J L Willems; Jan A J W Kluytmans
Journal:  J Clin Microbiol       Date:  2016-09-14       Impact factor: 5.948

10.  Appropriateness of empirical treatment and outcome in bacteremia caused by extended-spectrum-β-lactamase-producing bacteria.

Authors:  Florine N J Frakking; Wouter C Rottier; J Wendelien Dorigo-Zetsma; Jarne M van Hattem; Babette C van Hees; Jan A J W Kluytmans; Suzanne P M Lutgens; Jan M Prins; Steven F T Thijsen; Annelies Verbon; Bart J M Vlaminckx; James W Cohen Stuart; Maurine A Leverstein-van Hall; Marc J M Bonten
Journal:  Antimicrob Agents Chemother       Date:  2013-04-22       Impact factor: 5.191

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.